CA3236890A1 — Aldosterone synthase inhibitors for treating chronic kidney disease
Assigned to Boehringer Ingelheim International GmbH · Expires 2023-06-22 · 3y expired
What this patent protects
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I) and pharmaceutically acceptable salts thereof, wherein Cy, R1and R2 are as defined herein. The invention further relates to the use of the c…
USPTO Abstract
The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (I) and pharmaceutically acceptable salts thereof, wherein Cy, R1and R2 are as defined herein. The invention further relates to the use of the compounds of formula (I) in combination with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.